---

•	In-Depth Reports Home

In This Report

•

More Features

•	Printer-friendly version

Atrial fibrillation overview

Atrial fibrillation (AF) is the most common sustained arrhythmia in adults. It affects more than 2 million individuals in the United States, and as many as 160,000 new cases are diagnosed each year. The incidence of atrial fibrillation increases with age, and it is often associated with hypertension, valvular and pulmonary disease, metabolic disorders, and coronary artery disease. It is usually triggered by rapid firing from the pulmonary veins, followed by disorganized and asymmetrical impulse through the atria resulting in over 400 beats/min. The ventricles also respond in an irregular way. A serious consequence resulting from AF is clot formation in the atrium, especially when the atria have enlarged and have areas of pooling blood, which subsequently leads to embolism. Risk of thromboembolism is greater in people with diabetes, hypertension, history of embolism, diseases of the valves, and heart failure.

In atrial flutter, regular atrial rates range from 250 to 350 beats/min. Most people with atrial flutter have some type of underlying heart problem such as hypertension, coronary artery disease, pericarditis, or valvular heart disease. It can also be caused by a congenital heart defect. Atrial flutter increases the patient’s risk of thromboembolism by 3% per year. Prevention and treatment of atrial flutter should be approached as described for atrial fibrillation. Long-term anticoagulation therapy is recommended for both conditions to reduce the risk of thromboembolism. Radiofrequency catheter ablation is very effective and has minimal risks. It can even be considered as an alternative to drug therapy.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language.

© 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

All content on this site including text, images, graphics, audio, video, data, metadata, and compilations is protected by copyright and other intellectual property laws. You may view the content for personal, noncommercial use. Any other use requires prior written consent from Ebix. You may not copy, reproduce, distribute, transmit, display, publish, reverse-engineer, adapt, modify, store beyond ordinary browser caching, index, mine, scrape, or create derivative works from this content. You may not use automated tools to access or extract content, including to create embeddings, vectors, datasets, or indexes for retrieval systems. Use of any content for training, fine-tuning, calibrating, testing, evaluating, or improving AI systems of any kind is prohibited without express written consent. This includes large language models, machine learning models, neural networks, generative systems, retrieval-augmented systems, and any software that ingests content to produce outputs. Any unauthorized use of the content including AI-related use is a violation of our rights and may result in legal action, damages, and statutory penalties to the fullest extent permitted by law. Ebix reserves the right to enforce its rights through legal, technological, and contractual measures.

© 1997- All rights reserved.